Deborah Ascheim - Capricor Therapeutics Chief Medical Officer
| CAPR Stock | USD 18.62 0.83 4.67% |
Executive
Deborah Ascheim is Chief Medical Officer of Capricor Therapeutics since 2015.
| Age | 59 |
| Tenure | 9 years |
| Address | 10865 Road to the Cure, San Diego, CA, United States, 92121 |
| Phone | 858 727 1755 |
| Web | https://www.capricor.com |
Capricor Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4449) % which means that it has lost $0.4449 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9269) %, meaning that it created substantial loss on money invested by shareholders. Capricor Therapeutics' management efficiency ratios could be used to measure how well Capricor Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to drop to -0.4. In addition to that, Return On Capital Employed is likely to grow to -0.83. At this time, Capricor Therapeutics' Total Assets are relatively stable compared to the past year. As of 11/22/2024, Non Current Assets Total is likely to grow to about 8.3 M, while Other Current Assets are likely to drop slightly above 572 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alastair Leighton | MeiraGTx Holdings PLC | N/A | |
| Mick OQuigley | Ideaya Biosciences | N/A | |
| Kevin Shaw | NextCure | 49 | |
| MD JD | Cidara Therapeutics | N/A | |
| SPHR CCP | Cidara Therapeutics | N/A | |
| Eric Loumeau | AnaptysBio | 61 | |
| Beth Mueller | AnaptysBio | N/A | |
| Sourav Kundu | NextCure | 63 | |
| Andres CPA | Ideaya Biosciences | 38 | |
| Martin Dahl | AnaptysBio | N/A | |
| Michael White | Ideaya Biosciences | 58 | |
| Douglas Snyder | Ideaya Biosciences | 60 | |
| Pramod Gupta | Unicycive Therapeutics | 64 | |
| MBA Ashizawa | Bio Path Holdings | N/A | |
| Jim MBA | Cidara Therapeutics | N/A | |
| Francine Zelaya | Ideaya Biosciences | N/A | |
| Patricia Hirano | Soleno Therapeutics | 58 | |
| Paul Barsanti | Ideaya Biosciences | N/A | |
| Douglas MBA | AnaptysBio | 55 | |
| ScD MD | Moleculin Biotech | 72 | |
| Patricia MPH | Soleno Therapeutics | 58 | |
Management Performance
| Return On Equity | -3.93 | ||||
| Return On Asset | -0.44 |
Capricor Therapeutics Leadership Team
Elected by the shareholders, the Capricor Therapeutics' board of directors comprises two types of representatives: Capricor Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Capricor. The board's role is to monitor Capricor Therapeutics' management team and ensure that shareholders' interests are well served. Capricor Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Capricor Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Deborah Ascheim, Chief Medical Officer | ||
| Kristi Elliott, Chief Officer | ||
| Karen Krasney, Executive Vice President General Counsel | ||
| Xavier Avat, Chief Officer | ||
| MD FACC, Executive Board | ||
| Catherine Kelleher, Consultant | ||
| Eduardo Marbn, CoFounder Board | ||
| Anthony MBA, CFO Treasurer | ||
| Linda Marbn, President, CoFounder |
Capricor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Capricor Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.93 | ||||
| Return On Asset | -0.44 | ||||
| Profit Margin | (1.47) % | ||||
| Operating Margin | (5.75) % | ||||
| Current Valuation | 776.91 M | ||||
| Shares Outstanding | 45.47 M | ||||
| Shares Owned By Insiders | 16.72 % | ||||
| Shares Owned By Institutions | 18.51 % | ||||
| Number Of Shares Shorted | 5.28 M | ||||
| Price To Earning | 42.39 X |
Pair Trading with Capricor Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Capricor Stock
| 0.87 | NKTX | Nkarta Inc | PairCorr |
| 0.8 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.76 | CYRX | Cryoport | PairCorr |
| 0.75 | VALN | Valneva SE ADR | PairCorr |
| 0.73 | MTEM | Molecular Templates | PairCorr |
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.